European Group for Blood and Marrow Transplantation   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (1974)

Organization Overview

First Clinical Trial
2001
NCT01163942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

European Society for Blood and Marrow Transplantation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Aplastic (Phase 3)

Communicable Diseases (Phase 4)

Graft vs Host Disease (Phase 3)

Hepatic Veno-Occlusive Disease (Phase 3)

Hodgkin Disease (Phase 2)

Infections (Phase 4)

Invasive Fungal Infections (Phase 4)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Multiple Myeloma (Phase 3)

Mycoses (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 16